Affimed GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Affimed GmbH - overview
Established
2000
Location
Mannheim, -, Germany
Primary Industry
Biotechnology
About
Based in Heidelberg, Germany, and founded in 2000 by Melvyn Little, Affimed GmbH is a biopharmaceutical company engaged in developing unique antibody formats for the treatment of cancer, such as hematological and solid tumors as well as for inflammatory diseases. In January 2021, Affimed GmbH raised EUR 25 million in venture debt funding from Silicon Valley Bank. The company trades on Nasdaq under the ticker symbol AFMD. As of November 2021, Affimed GmbH employees approximately 153 employees and Adi Hoess is the CEO of the company.
Affimed GmbH develops multiple innate cell engagers, such as AFM13, AFM13 + Adoptive NK cells, AFM13 + ANTI-PD-1, AFM24, AFM24 + Adoptive NK cells, AFM24 + ANTI-PD-L1, AFM28, AFM32, Genentech, and ICE+ NK cell combination. AFM13 is ICE® (innate cell engager) molecule that benefits patients with CD30+ lymphomas. AFM24 is an EGFR-binding ICE® (innate cell engager) molecule that kills EGFR-expressing tumors. In addition, the company’s technology comprises ROCK® (redirected optimized cell-killing) platform that allows a molecular approach to generate customizable ICE® molecules.
Affimed GmbH has generated total revenue of EUR 28. 360 million in the fiscal year ended in December 2020. Affimed GmbH plans to use its proceeds from January 2021 funding to support the broad development strategy of its products.
Current Investors
OrbiMed Advisors, EQT Life Sciences, BioMed Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.affimed.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Affimed GmbH - financials
| Fiscal Year Ended | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - |
| EBITDA (USD) | - | - | - | - | - | - | - | - |
| Operating Income (USD) | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - |
| NET Income (USD) | 11,472,798.9 | (16,729,689.9) | (25,505,544.8) | (22,327,555.2) | (16,032,940.2) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.